We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Intestinal Fungi Contribute to Alcoholic Liver Disease

By LabMedica International staff writers
Posted on 08 Jun 2017
Chronic liver disease with cirrhosis is the 12th leading cause of death in the USA, and alcoholic liver disease accounts for approximately half of all cirrhosis deaths. More...
Chronic alcohol consumption is associated with intestinal bacterial dysbiosis, yet little is known about the contribution of intestinal fungi, or mycobiota, to alcoholic liver disease.

Intestinal fungi may contribute to the development of alcoholic liver disease (ALD), which encompasses a broad range of liver diseases, from simple steatosis (fatty liver) to end-stage liver disease, or cirrhosis (liver cell death). Patients with cirrhosis are either frequently exposed to fungal products or develop fungal infections, with high mortality.

Scientists at the University of California, San Diego (La Jolla, CA, USA) and the J. Craig Venter Institute (Rockville, MD, USA) used both a mouse model and human samples of serum and feces in their study. They analyzed human serum samples data collected from 28 patients with alcoholic liver cirrhosis from July 1, 2010, through October 31, 2010. The human fecal samples were from eight healthy individuals without chronic disease (controls), 10 alcohol-dependent patients without evidence of progressive liver disease (non-progressive liver disease), six patients with alcoholic hepatitis (alcoholic hepatitis) and four patients with alcoholic liver cirrhosis (alcoholic cirrhosis). Primary human hepatocytes, Kupffer cells, and hepatic stellate cells were isolated and RNA extraction and quantitative reverse transcriptase polymerase chain reaction (PCR) were performed.

The scientists observed that alcohol-dependent patients displayed reduced intestinal fungal diversity and Candida overgrowth. Compared with healthy individuals and patients with non–alcohol-related cirrhosis, alcoholic cirrhosis patients had increased systemic exposure and immune response to mycobiota. Moreover, the levels of extraintestinal exposure and immune response correlated with mortality. There were concomitant decreases in Epicoccum, unclassified fungi, Galactomyces, and Debaryomyces.

The authors concluded that alcohol-associated fungal dysbiosis in humans is characterized by a large increase in Candida, which is susceptible to amphotericin B. The effects of this drug should be tested in patients with alcohol-related liver disease, who are in urgent need of new therapeutics. Manipulation of the intestinal mycobiome might be an effective strategy for attenuation of alcohol-related liver disease.

Bernd Schnabl, MD, an associate professor of gastroenterology and senior author of the study, said, “Not only is this the first study to associate fungi and liver disease, we might be able to slow the progression of alcoholic liver disease by manipulating the balance of fungal species living in a patient’s intestine.” The study was published on May 22, 2017, in the Journal of Clinical Investigation.

Related Links:
University of California, San Diego
J. Craig Venter Institute

New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.